Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases  Carolyn A.

Slides:



Advertisements
Similar presentations
Transplantation For Scleroderma: Data from the Phase I/II Pilot Multicenter Study (FHCRC protocol 1019)
Advertisements

Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Copyright © 2010 American Medical Association. All rights reserved.
Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells  Marie Bleakley,
Stephanie J. Lee, Loretta A. Williams 
Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87%  Pooja.
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
George E. Georges, Vladimir Lesnikov, Szczepan W
CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma  Lawrence G. Lum, Archana Thakur, Qin Liu, Abhinav.
Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen– Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up.
Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma  Egil S. Blix, Anders.
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.
Total Colony-Forming Units Are a Strong, Independent Predictor of Neutrophil and Platelet Engraftment after Unrelated Umbilical Cord Blood Transplantation:
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies 
Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation.
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia  Robert Iannone, James F Casella, Ephraim.
Human CD4+CD25+ Cells in Combination with CD34+ Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity  Dolores Mahmud,
Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma  Kenneth R. Meehan, Laleh Talebian,
Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma  Egil S. Blix, Anders.
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
Cord Blood Units with Low CD34+ Cell Viability Have a Low Probability of Engraftment after Double Unit Transplantation  Andromachi Scaradavou, Katherine.
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
The Intravenous Route of Injection Optimizes Engraftment and Survival in the Murine Model of In Utero Hematopoietic Cell Transplantation  Matthew M. Boelig,
Haploidentical In Utero Hematopoietic Cell Transplantation Improves Phenotype and Can Induce Tolerance for Postnatal Same-Donor Transplants in the Canine.
FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal  Patricia A. Taylor,
Bone Marrow Transplantation Using HLA-Matched Unrelated Donors for Patients Suffering from Severe Combined Immunodeficiency  Eyal Grunebaum, MD, Chaim.
Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced- Intensity Conditioning Creates a Platform for Immunotherapy with Donor.
The Intravenous Route of Injection Optimizes Engraftment and Survival in the Murine Model of In Utero Hematopoietic Cell Transplantation  Matthew M. Boelig,
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection 
Characteristics of CliniMACS® System CD34-Enriched T Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant.
Stephanie J. Lee, Loretta A. Williams 
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine.
Reduced-Intensity Allogeneic Stem Cell Transplantation in Children and Young Adults with Ultrahigh-Risk Pediatric Sarcomas  Kristin Baird, Terry J. Fry,
Clinical trials of intracoronary bone marrow cell transfer after myocardial infarction: The Hannover experience  Helmut Drexler  Biology of Blood and.
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
A “No-wash” Albumin-Dextran Dilution Strategy for Cord Blood Unit Thaw: High Rate of Engraftment and a Low Incidence of Serious Infusion Reactions  Juliet.
Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases  Elizabeth O. Stenger, Kuang-Yueh Chiang, Ann.
Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog Leukocyte Antigen-Haploidentical Bone Marrow Transplantation 
Keith M. Sullivan, Paolo Muraro, Alan Tyndall 
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Volume 14, Issue 12, Pages (December 2017)
Quantitation of Human Cells that Produce Neutrophils and Platelets in Vivo Obtained from Normal Donors Treated with Granulocyte Colony–Stimulating Factor.
Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma  Mark Korthals, Nina Sehnke, Ralf Kronenwett,
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+
Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.
Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.
Evaluation of Initial Telomere Length and Changes after Transplantation in Adult Double-Unit Cord Blood Transplant Recipients  Beth Ashbridge, Ahmet Zehir,
Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.
CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased.
Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.
Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts  Dong Hwan Kim, Nazir Jamal, Ronnie.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:
Post-Thaw Viable CD45+ Cells and Clonogenic Efficiency are Associated with Better Engraftment and Outcomes after Single Cord Blood Transplantation in.
Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H
Richard Mitchell, John E. Wagner, Claudio G
Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation  J.R. Molina,
Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning  Junya Kanda, David.
Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma  Ivan Aksentijevich,
Real Time Immunophenotyping of Leukocyte Subsets Early after Double Cord Blood Transplantation Predicts Graft Function  Jianqiang Li, Ian Nicoud, Joseph.
Analysis of 402 Cord Blood Units to Assess Factors Influencing Infused Viable CD34+ Cell Dose: The Critical Determinant of Engraftment  Duncan Purtill,
Mary Eapen  Biology of Blood and Marrow Transplantation 
Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation  Filippo Milano, Shelly Heimfeld, Ted Gooley,
Cryopreserved CD34+ Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after.
Optimal Donor Selection: Beyond HLA
Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.
Presentation transcript:

Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases  Carolyn A. Keever-Taylor, Shelly Heimfeld, Kaitlyn C. Steinmiller, Richard A. Nash, Keith M. Sullivan, Christine W. Czarniecki, Tomeka C. Granderson, Julia S. Goldstein, Linda M. Griffith  Biology of Blood and Marrow Transplantation  Volume 23, Issue 9, Pages 1463-1472 (September 2017) DOI: 10.1016/j.bbmt.2017.05.018 Copyright © 2017 Terms and Conditions

Figure 1 Comparability of flow cytometry techniques at sites. The CD34+ cell depleted flow-through after Isolex, from a PBSC collection from a normal volunteer, was distributed into multiple aliquots in 15-mL centrifuge tubes (approximately 2 billion cells per sample, at a cell concentration of 1 to 2 × 108/mL). Site 01, where the samples originated, shipped tubes overnight for early morning receipt to 7 other sites and shipped a tube to itself to serve as an intralaboratory control (listed as 01). In addition to the 8 shipments, 1 study tube was retained in a refrigerator at the site of origin to serve as a control to assess effect of transport on product flow cytometry characteristics (listed as 01Ref). TNC measurement and flow cytometry analysis were performed at sites. (A) Percentage TNC Recovery was calculated by dividing the TNC result at each individual site by the TNC result for the reference tube stored at the site of origin (01Ref). (B-D) Percentages were calculated based on TNC (viable + nonviable) determined at the given site. In C, note that CD3+ data at site 07 was not available. Site 01,  FHCRC; Site 02,  City of Hope; Site 03,  Duke University; Site 04,  Medical College of Wisconsin; Site 05,  MD Anderson Cancer Center; Site 06,  Ohio State University; Site 07,  Dana Farber Cancer Institute; Site 08,  University of Michigan. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 2 Comparability of controlled rate cryopreservation at sites. The CD34-depleted flow-through after Isolex, from a PBSC collection from a normal volunteer, was distributed into multiple aliquots in 15-mL centrifuge tubes and shipped from Site 01 to the other sites and to Site 01 as described in Figure 1. Sites then processed the samples for cryopreservation in Cryocyte bags. The Cryocyte bags were subjected to controlled rate freezing at the sites, stored for 1 week, and then shipped back to Site 01 where they were thawed and measured for TNC and analyzed by flow cytometry. (A) Percent TNC Recovery was calculated by dividing the TNC result from each individual site by the TNC result from the thawed product at Site 01. (B-D) Percentages were calculated using TNC determined at the given site. Sites are as in Figure 1. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 3 Stability of normal donor Auto-CD34+ HPC with storage. CD34+ cell enrichment using Isolex was performed on PBSCs from a G-CSF mobilized normal volunteer, and the enriched CD34+ cells were aliquoted into 4 Cryocyte bags and subjected to controlled rate cryopreservation. Bags were thawed at 1 week and at 1, 3, and 6 months and measured for TNC and analyzed by flow cytometry. TNC recovery was calculated by dividing TNC at the respective time point by TNC in the initial product before cryopreservation. Percentage viable CD34+ cell recovery was calculated by dividing number of viable CD34+ cells at the respective time point by the number of viable CD34+ cells in the initial product before cryopreservation. Percentage viable CD3+ recovery was calculated similarly. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 4 Auto-CD34+HPC composition by study and device. By Device: Median percentage of viable CD34+ cells constituted well above the 70% specification, with lots prepared on CliniMACS having a higher percentage on average as compared with Isolex (A). Lots prepared on Isolex had a higher percentage of residual CD3+ cells on average, compared with CliniMACS (B). Final product viability met specifications for all lots with no more than 15% dead cells in lots processed on either device (F). The percentage of B cells, natural killer cells, and monocyte content was also analyzed (C, D, and E). B cell (range, 0% to 2.1%) and monocyte (range, .1% to 6%) content in the lots processed on CliniMACS was uniformly low. B cell (range, 0% to 38.9%) and monocyte (range, .01% to 26.6%) contamination was greater for the lots processed on Isolex. B cell content for lots processed on Isolex was >10%, with 12 lots having B cell content > 20%. Of note, lots from a given patient tended to have similar levels of B cell contamination (data not shown). Although the median proportion of monocytes was the same for both devices (.34%), 5 lots processed with Isolex had ≥4% monocytes, with 1 as high as 26.6%. Lots from both devices had very low numbers of natural killer cells (<5.5%). By Study: The composition of lots prepared from patients on the HALT-MS and SCOT studies were very similar (A-F). Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 5 Days from start of collection to transplant by study. The number of days Auto-CD34+HPC were stored after apheresis collection, CD34+ selection, and cryopreservation, before infusion on the day of transplant, is illustrated for HALT-MS and for SCOT. The number of days was calculated from the start of collection to the day of transplant. Collection may have occurred over a series of days to ensure an adequate dose. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 6 Viable dose per kg administered by study. Graft dose was calculated as viable cells administered/kg RBW. (A,B) Doses meeting or exceeding target CD34+ dose for each respective study are shaded in red (A). Mean doses are denoted with the filled diamond. To achieve these doses, subjects received a mean and median of 2 lots of Auto-CD34+HPC per subject (Table 1C). For HALT-MS, endpoint status was event-free survival (EFS), defined as survival without death or disease activity from any one of disability progression, relapse, or new lesions on magnetic resonance imaging (C,D). Participants were evaluated through 5 years post-transplant. For SCOT, endpoint status was EFS, defined as survival without death or organ failure (C,D). Organ failure included respiratory failure defined as decrease in diffusing capacity of the lung for carbon monoxide > 30% or forced vital capacity > 20% from baseline, renal failure defined as requiring dialysis or renal treatment, or cardiac failure defined as left ventricular ejection fraction < 30% or New York Class III. Participants were evaluated through 54 months post-transplant. All HALT-MS subjects had their products processed on the Isolex, whereas SCOT subjects had their products processed on either the CliniMACs or the Isolex device. Of the 8 subjects on SCOT who met endpoint, 1 (12.5%) had their graft prepared on CliniMACs and 7 (87.5%) had their graft prepared on Isolex. Similarly, of the 25 SCOT subjects who did not meet endpoint, 5 (20.0%) had their graft prepared on CliniMACs and 20 (80.0%) had their graft prepared on Isolex. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions

Figure 7 Engraftment kinetics by study. Neutrophil recovery: For HALT-MS, neutrophil engraftment was defined as absolute neutrophil count > 500/µL for 2 consecutive readings. For SCOT, neutrophil engraftment was defined as absolute neutrophil count >500/µL for 3 readings on consecutive days. Platelet recovery: Days to last platelet transfusion was calculated from date of transplant. We note recovery of platelet counts > 20,000/ µL could be expected to be about 7 days after the last platelet transfusion for HALT-MS or SCOT subjects. However, these data were not documented precisely for our studies, as some individuals were discharged from the transplant center and therefore did not receive daily platelet counts in this timeframe. (A and B) The mean is denoted with the filled diamond. (C and D) Pearson correlations are presented as a measure of association. Biology of Blood and Marrow Transplantation 2017 23, 1463-1472DOI: (10.1016/j.bbmt.2017.05.018) Copyright © 2017 Terms and Conditions